FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Lucera Erick</u>				<u>S</u> A	2. Issuer Name and Ticker or Trading Symbol SAB Biotherapeutics, Inc. [ SABS ]							(Ch	elationship eck all applic	cable)	Pers	on(s) to Issu 10% Ow		
(Last)	(F	irst)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 07/15/2024							Officer below)	(give title		Other (s below)	pecify		
777 W 4 SUITE 4					4. l	f Amei	ndment, l	Date	of Original F	iled	(Month/Da	ay/Year)	Line	<u></u>	Joint/Group			
(Street)	BEACH F	Г	33140		-										iled by More		J	- 1
, WITAIVII I	DEACH F	L	33140	Rule 10b5-1(c) Transaction Indication														
(City)	(5	state)	(Zip)	Check this box to indicate that a transaction was made pursuant to satisfy the affirmative defense conditions of Rule 10b5-1(c). See In								n or written p	lan tha	at is intended	to			
		Tab	le I - Non	-Deriv	/ative	e Sec	curities	s Ac	quired, [	Disp	osed o	f, or Be	neficiall	y Owned				
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Execution Date,		Transaction Disposed Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		Beneficia	es ally Following	Form:	Direct of Indirect If str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	V	Amount	(A) or (D)	Price	Transact (Instr. 3	ion(s)			(111511.4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Security or Exercise (Month/Day/Year)   Execution Date, if any				ransaction of ode (Instr. Derivative		Expiration Date (Month/Day/Year) U			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares					
Stock Option (right to buy) <sup>(1)(2)</sup>	\$2.9	07/15/2024			A		20,000		(1)	0	7/15/2034	Common Stock	20,000	\$0	20,000		D	

## **Explanation of Responses:**

- 1. Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026.
- 2. This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

/s/ Erick Lucera

07/17/2024

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.